Volume | 6,532,577 |
|
|||||
News | - | ||||||
Day High | 48.55 | Low High |
|||||
Day Low | 47.70 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
48.44 | 47.70 | 48.55 | 48.26 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
65,777 | 6,532,577 | $ 48.15 | $ 314,563,043 | - | 47.58 - 70.935 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:28:55 | bunched | 255 | $ 47.9787 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
97.05B | 2.02B | - | 45.01B | 8.03B | 3.97 | 12.09 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 51.21 | 51.285 | 47.70 | 48.88 | 11,918,401 | -3.22 | -6.29% |
1 Month | 51.62 | 54.475 | 47.70 | 51.34 | 11,371,740 | -3.63 | -7.03% |
3 Months | 50.20 | 55.035 | 47.58 | 51.04 | 15,901,453 | -2.21 | -4.40% |
6 Months | 57.06 | 57.645 | 47.58 | 51.19 | 15,538,988 | -9.07 | -15.90% |
1 Year | 70.60 | 70.935 | 47.58 | 55.62 | 12,606,671 | -22.61 | -32.03% |
3 Years | 65.42 | 81.435 | 47.58 | 63.97 | 11,520,325 | -17.43 | -26.64% |
5 Years | 46.15 | 81.435 | 41.19 | 60.96 | 12,295,509 | 1.84 | 3.99% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |